Nucleic Acid Therapeutics Synthesis

With over 15 years of dedicated experience in nucleic acid synthesis, BiOligo operates on a mature oligonucleotide chemistry platform supported by a comprehensive quality control system. Through continuous technical innovation, we provide high-purity oligonucleotides required across key development stages, including early discovery, in vivo studies, and process scale-up, offering a one-stop solution for small nucleic acid therapeutics development.

siRNA                miRNA                   ASO                        Aptamer                           saRNA
 

Product Features

High Conjugation Efficiency

  • Extensive experience in synthesis and conjugation, enabled by proprietary and innovative coupling technologies, achieving single-step coupling efficiencies of up to 99.6%
  • 200+ modifications available, with multiple conjugation options including GalNAc, lipids, and small-molecule moieties

Comprehensive and Customizable Quality Control System

  • 100+ QC methods available, covering LC-MS/MS, HPLC, chiral analysis, residual solvents, and endotoxin testing, .etc
  • QC strategies can be tailored based on modification type, stereochemistry, and development stage, ensuring alignment with project-specific and regulatory expectations

High Purity

  • Purified by 100% HPLC, with ≥90% purity, suitable for pharmacodynamic evaluation, delivery system assessment, and in vivo animal studies.

Flexible Synthesis Scale

  • Oligonucleotide synthesis ranging from nmol to hundred-gram scale, supporting RUO through GMP-grade manufacturing requirements

Rapid Turnaround Time

  • Standard research-grade oligonucleotides can be delivered within 3–7 business days, supporting rapid iteration during early-stage development

 

Reliability and Compliance

  • Pharmaceutical GMP–certified manufacturing capabilities
  • 10+ invention patents and 20+ utility model patents related to nucleic acid synthesis, supported by additional proprietary and non-public technologies for specialized modifications and conjugation
  • Validated siRNA silencing efficiency ≥75%
  • Complete batch documentation and traceability system to support consistent and robust quality management